Access to treatment for HBV infection and its consistency with 2008 European guidelines in a multicentre cross-sectional study of HIV/HBV co-infected patients in Italy

Table 1 Characteristics of the 427 patients with HIV/HBV co-infection according to anti-HBV treatment status

Characteristics	Never treated patients (n = 53)	Treated patients (n = 374)	All patients (n = 427)	P
N. enrolled per center, %
≥20 patients	60.4	52.9	53.9	0.31
Female gender, %	22.6	24.3	24.1	0.79
Immigrant status, %
foreign birth	18.9	16.8	17.1	0.71
Median age at diagnosis^§, years
(IQR)	35 (31–43)	35 (29–42)	35 (30–42)	0.81
Years since HBV diagnosis°, %				<0.001
<2	32.1	7	10.1
2-10	52.8	59.9	59
>10	15.1	32.4	30.2
Alcohol consumption^*, %				0.22
never	15.1	18.7	18.3
ever	60.4	47.6	49.2
not available	24.5	33.7	32.6
Disease stage, %
cirrhosis/HCC	3.8	9.4	8.7	0.18
HBeAg, %				0.17
positivity	28.3	35.8	34.9
not available	1.9	0.3	0.5
HCV co-infection, %				0.4
yes	24.5	33.4	32.3
not available	--	0.3	0.2
HDV co-infection, %				0.07
yes	7.5	19.8	18.3
not available	9.4	5.9	6.3

^§computed on 424 patients; °3 patients not available; * ≥ 20 g/day during at least 6 consecutive months life-time; IQR, interquartile range; HCC, hepatocellular carcinoma.